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Purpose: Recurrence rate is considered a better measure of clinical outcomes after 
thymoma resection than overall survival due to the indolent behavior of thymo-
mas. This study was designed to determine predictors of recurrence after thymoma 
resection. Materials and Methods: A single-institution, retrospective study was 
performed, including 305 patients who had undergone thymoma resection be-
tween 1986 and 2009. Results: Among 305 patients, recurrence was observed in 
41 patients (13.4%). The recurrence rates were 0% (0/19), 6.3% (4/63), 4.2% 
(2/48), 18.6% (11/59) and 20.7% (24/116) for type A, AB, B1, B2 and B3 tumors, 
respectively. The recurrence rate according to Masaoka stage was 6.1% (8/132), 
11.4% (13/114), 26.8% (11/41) and 50.0% (9/18) for stages I, II, III and IV, re-
spectively. After univariate analysis, completeness of resection (R0 versus R1), 
World Health Organization (WHO) histologic type (A, AB, B1 versus B2, B3), 
Masaoka stage, and size of tumor (<8 cm versus ≥8 cm) demonstrated significant 
differences with freedom from recurrence. Upon multivariate analysis, Masaoka 
stage was the only independent predictor of recurrence. Conclusion: WHO histo-
logic type, Masaoka stage, and size of tumor were associated with recurrence. Par-
ticularly, Masaoka stage was the only independent predictor of recurrence after 
thymoma resection.
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INTRODUCTION
Thymomas are tumors that originate from thymic epithelial cells, demonstrating 
organotypic features. They are the most common mediastinal tumor, accounting 
for approximately 20% of all mediastinal masses and up to 50% of all anterior me-
diastinal masses.1 However, because thymomas involve a wide spectrum of histo-
logical, biological and oncological characteristics, not only are there no uniform 
guidelines concerning the management thereof, but outcomes after management 
and subsequent prognoses have also not been well established. Thus, the Interna-
tional Thymic Malignancy Interest Group (ITMIG) has attempted to establish 
standard definitions and policies for thymoma management. ITMIG has suggested 
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served. For example, when the tumor had both B2 and B3 
components, the tumor was classified as type B3. Tumor 
stage was classified into I, II, III, IVa, IVb, following the 
Masaoka classification system;8 stage was determined by 
review of surgical records and pathological reports. 
Surgery
Extended thymectomy was defined as the resection of the 
entire thymus and mediastinal fat tissue between both phren-
ic nerves. Thymomectomy was defined as the resection of 
the thymoma along with the surrounding fatty tissue, leav-
ing residual thymic tissue.10
Complete thymectomy has been widely supported for 
thymoma resection. However, in some patients without my-
asthenia gravis, we performed thymomectomy at the dis-
cretion of the surgeon, depending on the location and size 
of thymoma. This policy was supported by the results of a 
previously published report by our institution in which no 
difference in survival between extended thymectomy and 
thymomectomy was noted.10
Completeness of resection was categorized as follows: 
R0 resection indicated no residual tumor tissue; R1 resec-
tion indicated microscopic residual tumor tissue; and R2 re-
section indicated macroscopic residual tumor tissue; R2 pa-
tients were excluded from this study. Patients with stage 
IVa tumors that were completely removed, including all of 
the involved pleural and pericardial lesions, were classified 
as a R0 resection. 
Adjuvant therapy
Our strategies for adjuvant therapy were as follows: no ad-
juvant therapy for stage I thymomas, radiotherapy for inva-
sive or incompletely resected thymomas, and chemothera-
py (with or without radiotherapy) for Masaoka stage IV 
thymomas. However, because this strategy was not stan-
dardized for the entire study period, the strategy for adju-
vant therapy was patient specific according to each sur-
geon’s preference.
Adjuvant chemotherapy was generally performed ac-
cording to the ADOC regimen (doxorubicin, cisplatin, vin-
cristine, and cyclophosphamide) for a total of 6 cycles ev-
ery 3-4 weeks. 
Radiotherapy was applied at a median dose of 5040 cGy 
(180 cGy/fraction, range, 4500 to 6300 cGy) for 5-6 weeks. 
Follow up
All patients were followed up at the outpatient clinic at 
that freedom-from-recurrence is a better measure than sur-
vival in patients who have successfully undergone curative-
intent treatment.2 Their reasoning for this was that thymo-
mas progress slowly, and thus, many patients die of causes 
unrelated to the thymoma. In actuality, only -50% of fatali-
ties are due to the thymoma or the treatment thereof. Ap-
proximately, 20% of deaths are due to myasthenia gravis, 
and 10% result from autoimmune disorders associated with 
thymoma. The remaining deaths have been attributed to un-
related conditions, including other malignancies.1 Accord-
ingly, recurrence may more accurately reflect clinical out-
comes after resection than survival. 
Several factors, such as Masaoka stage, World Health 
Organization (WHO) histological type, completeness of 
resection, and tumor size have been shown to be prognos-
tic factors influencing survival after thymoma resection.3-8 
Compared to the studies on survival, only a few reports 
have addressed predictive factors of recurrence.5,9 
Therefore, we conducted a retrospective study to deter-
mine predictors of recurrence after thymoma resection. 
MATERIALS AND METHODS
　　　
Patients 
The Institutional Review Board of Yonsei University Col-
lege of Medicine approved this retrospective study. The 
need for individual consent from patients whose records 
were evaluated was waived because individuals were not 
identified in the study. 
Four hundred and eleven consecutive patients underwent 
surgery for a thymic epithelial tumor at our institute between 
January 1986 and December 2009. Of those, we excluded 
patients with an undetermined WHO histologic type (n=19) 
due to the unavailability of specimen slides or a total infarct-
ed tumor; patients with type C thymoma (n=68); and pa-
tients who only underwent an open biopsy or R2 resection 
(n=19). The medical records of the remaining 305 patients 
were reviewed retrospectively. 
Histology and staging
Pathological results were confirmed by an experienced pa-
thologist (W.I. Yang) who was blind to the clinical data. The 
thymomas were classified into histological types A, AB, B1, 
B2 and B3, according to the WHO classification system.7 
When a tumor exhibited mixed histologic types, the tumor 
was classified as the most histologically aggressive type ob-
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RESULTS
 
Clinical characteristics and recurrence 
The characteristics of the patients and tumors are listed in 
Table 1. 
Recurrence was observed in 41 (13.4%) of the 305 pa-
3-month intervals for the first year, at 6-month intervals for 
the subsequent year, and yearly for the next 3 years. A physi-
cal examination and chest radiography were performed 
upon each visit to the outpatient clinic. A chest computed to-
mography (CT) was performed at 6-month intervals for the 
first 2 years and at 1-year intervals for the subsequent 3 
years. However, there was some variation in the follow-up 
procedure that was followed depending on the stage and 
histology of each tumor, as well as the surgeon’s prefer-
ence. After 5 years, patients were followed up at our neu-
rology or oncology department for any prevailing medical 
problems. The data for the nine patients who did not attend 
follow-up sessions were obtained by direct telephone con-
tact for this study. Follow-up for this study was complete 
up to December 2010. 
Definition of recurrence
Recurrence was divided into three categories according to 
the definition proposed by ITMIG.2 Local recurrence was 
defined as disease appearing in the anterior mediastinum or 
tissues immediately contiguous with the resected thymoma 
(i.e., pleural recurrence in the area of a previously resected 
stage IVa tumor, cervical lymph node adjacent to a previ-
ously resected thymoma). Regional recurrence was defined 
as intrathoracic recurrence (i.e., pleural and pericardial nod-
ules). Distant recurrence included extrathoracic recurrence 
and intraparenchymal pulmonary nodules.
Statistical analysis
Comparative analyses to identify differences in patient and 
tumor characteristics were performed using the χ2 test. 
Fisher’s exact test was conducted to analyze categorical 
variables, and Student’s t-test was used for continuous 
variables. Freedom from recurrence was calculated using 
the Kaplan-Meier method, and statistical differences in re-
currence were determined using the log-rank test. Recur-
rence of thymoma was considered as an event. All deaths 
without recurrence were considered as censored observa-
tions. The recurrence free period after the resection was 
calculated from the date of the resection to the date of the 
last follow-up or of recurrence diagnosis. For multivariate 
analysis, a Cox proportional hazards regression model 
was performed. A p-value of less than 0.05 was consid-
ered statistically significant. All statistical analysis was 
performed using SPSS software version 18.0 for Windows 
(Statistical Package for Social Science, SPSS Inc., Chica-
go, IL, USA).
Table 1. Patient and Tumor Characteristics
Variables Number %
Age, median (range), yrs 47 (17-83)
Sex
    Male 167 54.8
    Female 138 45.2
Myasthenia gravis
    No 137 44.9
    Yes 168 55.1
Approach of surgery
    Sternotomy 188 61.6
    Thoracotomy   52 17.0
    VATS   56 18.4
    Clamshell     4   1.3
    Cervicotomy     3   1.0
    RATS     2   0.7
Extent of resection
    Extended thymectomy 228 74.8
    Thymomectomy   77 25.2
Completeness of resection
    R0 276 90.5
    R1   29   9.5
WHO histologic type
    A   19   6.2
    AB   63 20.7
    B1   48 15.7
    B2   59 19.3
    B3 116 38.0
Masaoka stage 
    I 132 43.3
    II 114 37.4    
    III   41 13.4
    IVa   14   4.6
    IVb     4   1.3
Size of tumor
    Median (range), cm 5.8 (0.6-16.5)
Adjuvant therapy
    None 155 50.8
    Radiotherapy 106 34.7
    Chemotherapy     6   2.0
    CCRTx   38 12.5
CCRTx, concurrent chemoradiotherapy; RATS, robotic-assisted thoracic 
surgery; VATS, video-assisted thoracic surgery; WHO, World Health Orga-
nization.
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seven from unknown causes, four from cardiovascular dis-
ease, three from respiratory failure due to myasthenia gra-
vis, two from a traffic accident, one from liver cirrhosis, 
one from primary lung cancer, one from hepatocellular car-
cinoma and one from delayed mediastinitis.
The overall survival rates at 5, 10 and 15 years were 89.8, 
82.9 and 74.9%, respectively (Fig. 1).   
Freedom from recurrence
Recurrence rate according to the identified variables and 
freedom from recurrence over time are shown in Table 3.
In the univariate analysis, no significant differences in 
freedom from recurrence were observed according to age, 
sex, presence of myasthenia gravis and extent of resection. 
In cases of R1 resection, higher WHO histological type (B2, 
B3), advanced Masaoka stage, larger thymoma size (≥8 
cm) and no adjuvant therapy, a higher risk of recurrence 
was observed. The differences in freedom from recurrence 
between these groups are shown in Fig. 2. 
In multivariate analysis after adjusting for all the signifi-
cant variables of the univariate analysis, no significant rela-
tionships were found. 
However, as adjuvant therapy was shown to be signifi-
cantly correlated with Masaoka stage, a separate Cox regres-
sion analysis was performed excluding adjuvant therapy. In 
this multivariate analysis, Masaoka stage III and IV were 
shown to be independent predictors of tumor recurrence 
(stage III, hazard ratio, 3.912; 95% confidence interval, 
1.302 to 11.751; p=0.015, stage IV, hazard ratio, 5.236; 95% 
confidence interval, 1.407 to 19.482; p=0.014) (Table 4).
DISCUSSION
Our study showed that WHO histological type, Masaoka 
stage, and size of tumor are associated with recurrence after 
thymoma resection. In addition, Masaoka stage was shown 
to be the only independent predictor of recurrence after thy-
moma resection. These findings corroborate many previous 
tients. The median time to recurrence was 52 months (range, 
6 to 234 months). Six patients (14.6%) demonstrated local 
recurrence, 24 (58.5%) regional recurrence, 5 (12.2%) dis-
tant metastasis, and 6 patients (14.6%) demonstrated over-
lapped recurrence (4 local/regional, 1 local/distant, and 1 
regional/distant). Distant metastases were found in 7 pa-
tients: four lung, two liver, and one abdominal lymph node 
metastases. 
The recurrence rates were 0.0% (0/19), 6.3% (4/63), 4.2% 
(2/48), 18.6% (11/59) and 20.7% (24/116) for type A, AB, 
B1, B2 and B3 tumors, respectively. The recurrence rates 
according to Masaoka stage were 6.1% (8/132), 11.4% 
(13/114), 26.8% (11/41), 50.0% (7/14) and 50.0% (2/4) for 
stages I, II, III, Iva and IVb, respectively. 
Recurrence rates according to WHO histological type 
and Masaoka stage are shown in Table 2.
Survival     
After a median follow-up of 67 months (range, 2 to 241 
months), 239 (78.4%) patients were alive and well, 24 (7.9%) 
were alive with recurrence and 42 (13.8%) had died. Of 
those who died, 22 (52.3%) died of thymoma or treatment 
related causes, and the remaining 20 patients died due to 
other causes. The other causes of death were as follows: 
Table 2. Frequency of Recurrence According to Histologic Type and Stage
Stage/histology A AB B1 B2 B3 Total
I   0/10   0/42   0/32   5/28   3/20   8/132 (6.1%)
II 0/9   3/19   1/13   1/17   8/56 13/114 (11.4%)
III 0/0 1/2 1/3 2/8   7/28   11/41 (26.8%)
IVa 0/0 0/0 0/0 3/6 4/8     7/14 (50.0%)
IVb 0/0 0/0 0/0 0/0 2/4       2/4 (50.0%)
Total 0/19 (0.0%) 4/63 (6.3%) 2/48 (4.2%) 11/59 (18.6%) 24/116 (20.7%) 41/305 (13.4%)
Fig. 1. The overall survival of patients who underwent thymoma resection. 
The 5-, 10- and 15-year survival rates were 89.8, 82.9 and 74.9%, respectively.
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pendent predictor of recurrence after thymoma resection.
Wright12 suggested that a tumor size of 8 cm or larger was 
an independent risk factor of recurrence, and that large 
masses in which invasiveness is not clearly observable on 
CT are likely to be treated as stage III tumors. Our results 
also showed that a tumor size of 8 cm or larger was signifi-
cantly associated with recurrence.
In our study, the most frequently observed histological sub-
type was B3 (38%), followed by AB (20.7%), B2 (19.3%), 
B1 (15.7%) and type A (6.2%). However in a study by Mar-
garitora, et al.,13 which analyzed 317 patient (including some 
with WHO type C tumors), type B2 tumors were most fre-
quently observed (57.5%), followed by types B1 (19.2%), 
AB (9.5%), B3 (8.2%) and type A (3.5%). This difference 
could have been due to their high incidence rate of myas-
studies concerning prognostic factors of survival after thy-
moma resection.5,9
According to WHO histological type, histologic type A, 
AB and B1 thymomas demonstrated a lower risk of recur-
rence than types B2 and B3 in this study. Similar to these 
results, Ströbel, et al.11 reported that types A, AB and B1 
behaved in a benign fashion, while types B2 and B3 be-
haved malignantly. Okumura, et al.3 also reported that type 
B2 and B3 tumors were more malignant in nature, in terms 
of tumor recurrence, compared with types A, AB and B1. 
Regarding stage, Detterbeck1 reported that average recur-
rence rates were low for Masaoka stage I tumors (3%), but 
increased progressively to 11 and 30% for stage II and III 
tumors, respectively. Our observations corroborated these 
findings and showed that Masaoka stage was the only inde-
Table 3. Univariate Analysis of Predictive Factors of Freedom from Recurrence after Thymoma Resection
Variables
Number 
(n=305)
Recurrence
5-yr* 10-yr* 15-yr* p value
n %
Age 0.064
    ≤47 yrs† 165 31 18.8 89.0 75.1 65.7
    >47 yrs 140 10   7.1 90.4 88.6 88.6
Sex 0.341
    Male 167 21 12.6 90.8 81.3 74.5
    Female 138 20 14.5 88.5 78.1 68.3
Myasthenia gravis 0.986
    No 137 20 14.6 95.8 80.7 70.6
    Yes 168 21 12.5 96.6 79.0 66.3
Extent of resection 0.558
    Extended thymectomy 228 31 13.6 95.5 80.3 65.5
    Thymomectomy   77 10 13.0 98.4 80.0 75.3
Completeness of resection 0.005
    R0 276 32 11.6 92.6 82.1 74.6
    R1   29   9 31.0 68.9 64.8 64.8
WHO histologic type <0.0001
    A, AB, B1 130   6   4.6 97.3 90.2 90.2
    B2, B3 175 35 20.0 84.8 73.1 61.7
Masaoka stage <0.0001
    I 132   8   6.1 98.8 89.5 85.6
    II 114 13 11.4 90.7 79.0 79.0
    III   41 11 26.8 74.8 74.8 31.2
    IV   18   9 50.0 52.4 32.8 32.8
Size of tumor 0.021
    <8 cm 216 22 10.2 92.4 86.0 73.9
    ≥8 cm   89 19 21.3 83.7 66.7 66.7
Adjuvant therapy <0.0001
    No 154 12   7.8 96.2 88.4 80.0
    Yes 151 29 19.2 83.6 71.2 64.1
WHO, World Health Organization.
*Freedom from recurrence. 
†Median age.
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patients (18.4%) and by reclassifying these combined tu-
mors according to our classification, B3 tumors would have 
been recorded in 71 patients (31%).11 Their distribution of 
histological types was similar to ours.
thenia gravis (87%) and differences in our classification 
system, which classified mixed type tumors as the higher 
component type. Ströbel, et al.11 reported on 28 type B3 tu-
mors (12.3%) out of 228 patients and B2+B3 tumors in 42 
Fig. 2. Freedom from recurrence curves according to completeness of resection (A), WHO histological classification (B), Masaoka stage (C), size of tumor 
(D) and adjuvant therapy (E).
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were considered to have successfully undergone curative-
intent treatment. Finally, our follow-up method of five years 
after thymoma resection was not appropriate to confirm re-
currence. We included nine patients who were followed-up 
by phone call as having no recurrence; however, because 
we were not able to check their medical status, we were not 
able to confirm their reports. Additionally, for patients fol-
lowed-by the neurology department, they did not undergo 
regular chest CTs; therefore, recurrence may have been 
missed resulting in an underestimated recurrence rate. 
In conclusion, WHO histologic type, Masaoka stage and 
size of tumor were shown to be associated with recurrence 
after thymoma resection. Particularly, Masaoka stage was 
the only independent predictor of recurrence after thymoma 
resection. 
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